VNDA — Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Net Product Sales: $51.7 million, a 3% increase year-over-year from $50 million in Q1 2025, but a 10% decrease from $57.2 million in Q4 2025.
• Fanapt Sales: $29.6 million, up 26% year-over-year from $23.5 million in Q1 2025, but down 11% from $33.2 million in Q4 2025.
• Hetlioz Sales: $15.9 million, a 24% decrease year-over-year and a 3% decrease from Q4 2025.
• Ponvory Sales: $6.2 million, a 10% increase year-over-year but an 18% decrease from Q4 2025.
• Net Loss: $48.6 million, compared to a net loss of $29.5 million in Q1 2025.
• Operating Expenses: $101.9 million, up from $91.1 million in Q1 2025, primarily due to increased SG&A expenses.
• Cash Position: $202.3 million, a decrease of $61.5 million from the end of 2025.

2. Strategic Updates and Business Highlights

• Fanapt Growth: Continued strong performance with total prescriptions (TRx) up 32% and new-to-brand prescriptions (NBRx) up 76% year-over-year.
• Nirius Launch: Successfully launched with a direct-to-consumer platform, targeting a market of 70 million people suffering from motion sickness.
• Dysanti Approval: Recently approved for bipolar I disorder and schizophrenia, with plans for a commercial launch in the latter half of 2026.
• Pipeline Progress: Ongoing late-stage studies for Dysanti and VQW-765, with expected results in 2026 or early 2027.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised to $240 million to $290 million, including $10 million to $30 million from Nirius.
• Fanapt Sales Guidance: Expected between $150 million and $170 million, implying approximately 36% growth compared to 2025.
• Other Product Sales: Anticipated to be between $80 million and $90 million, with Hetlioz expected to decline due to generic competition.

4. Bad News, Challenges, or Points of Concern

• Declining Hetlioz Sales: Facing significant pressure from generic competition, leading to a 24% year-over-year decline.
• Cash Burn: Expected to be greater in 2026 compared to 2025, raising concerns about financial sustainability.
• Insurance Plan Disruptions: Impacting sales and inventory management, particularly for Fanapt, which saw a decrease in TRx from Q4 2025.
• Recruitment Challenges: Slower patient recruitment for clinical studies, particularly for the long-acting injectable formulation of iloperidone.

5. Notable Q&A Insights

• Nirius Sales Expectations: The $10 million to $30 million guidance is based on market modeling rather than historical data, reflecting uncertainty in early launch performance.
• Dysanti Launch Strategy: The company aims to differentiate Dysanti from Fanapt, with expectations of independent demand rather than cannibalization.
• Long-acting Injectable Formulation: Concerns about recruitment speed and placebo relapse rates in ongoing studies, prompting potential discussions with the FDA for a modified development plan.
• Pricing Strategy for Nirius: Positioned competitively within the NK1 class, with a cash-pay model offering significant discounts to enhance patient access.

Overall, Vanda Pharmaceuticals is navigating a complex landscape with promising growth in certain areas, particularly Fanapt and the recent launch of Nirius, while facing challenges related to competition, cash management, and clinical study recruitment.